MetaCap

Theriva Biologics (TOVX) vs Exicure (XCUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Exicure is the larger company by market cap ($5.9 million vs $5.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TOVX-48.72%XCUR-11.75%
+22%-15%-52%
Oct 7, 20261 yearNov 20, 2026
TOVX-44.70%XCUR-14.28%
+9%-19%-47%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TOVX versus XCUR key metrics
MetricTOVXXCUR
Share price$0.12$0.9001
Market cap$5.51M$5.89M
1-day change-6.25%-12.82%
YTD return-42.86%—
1-year return-45.45%—
5-year return-99.86%—
P/E ratio (TTM)0.10—
EPS (TTM)$1.15$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-23.74M$-4.95M
52-week high$0.49$9.48
52-week low$0.12$0.777
Distance from 52-week high-75.51%-90.51%
Analyst consensusnone—
Avg. price target upside+1983.33%—
Average volume2.02M53.56K
Shares outstanding45.89M6.55M
Employees151
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Theriva Biologics

TOVX stock →

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Exicure

XCUR stock →

Exicure, Inc. does not have significant operations.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

TOVX vs XCUR FAQ

Which is bigger, Theriva Biologics or Exicure?

Exicure (XCUR) is larger, with a market capitalization of $5.89M compared with $5.51M for Theriva Biologics (TOVX).

Are Theriva Biologics and Exicure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons